Eli Lilly’s 2025 buying spree: What’s behind it?
This issue of our newsletter is supported by Crown Bioscience.
This year has seen Eli Lilly sign several licensing deals to bolster its position across a range of therapeutic areas. The company kicked off the year by collaborating with Alchemab Therapeutics to discover and develop five antibodies to treat ALS. Soon after this, it also announced a $99 million collaboration with Mediar Therapeutics for yet another antibody, but this time around, for the chronic respiratory illness idiopathic pulmonary fibrosis. And more deals followed.
Eli Lilly’s 2024 fourth quarter could point to why Eli Lilly has been enthusiastic about ramping up R&D partnerships. Its revenue almost doubled – 45% – to $13.53 billion since last year. Much of this is thanks to the whopping sales of Mounjaro and Zepbound, with Mounjaro alone bringing in $3.5 billion towards the end of 2024.?
To find out more, read the full article: “Over $3 billion in a month: Why is Eli Lilly starting 2025 on a buying spree?”
A MESSAGE FROM OUR SPONSOR CROWN BIOSCIENCE
Accelerating your ADC drug discovery pipeline
Navigating the complexities of ADC development—such as poor therapeutic windows, tumor heterogeneity, and off-tumor effects—requires precise target and lead selection. Crown Bioscience, with the largest library of patient-derived systems, including PDX models and organoids, provides unmatched target validation. Advanced engineering capabilities, including the creation of isogenic pairs and resistant models, optimize ADCs for greater efficacy.
?? Learn more
Want to advertise with us? Become our next sponsor.
?? More noteworthy articles from this week:
When U.S. President Donald Trump declared trade tariffs, it led to a global frenzy over a potential trade war. While the 25% tariffs imposed on Canada and Mexico have been shelved for a month, a 10% tariff was slammed on Chinese goods, after which, China clapped back with a 15% border tax on imports of certain U.S. fuel products. Now, the President has announced plans to slap 25% tariffs on all pharmaceuticals and semiconductor chips. As the economic war escalates, how do these tariffs affect the biopharma industry?
Hunter syndrome, also known as mucopolysaccharidosis type II (MPS II), is a rare genetic disorder affecting children – almost exclusively boys – that causes an abnormal accumulation of complex sugars in cells. Currently, there is no cure for Hunter syndrome, but biotechs are pursuing different methods of tackling the disease, with several candidates in clinical trials that are showing promise. In this article, we explore the three main technology approaches for treating Hunter syndrome.?
With the demand for organ transplants at an all-time high, it is no secret that we are currently in the midst of an organ shortage crisis. Fortunately, the biotech industry is working on innovative ways to solve this problem. In this article, we take a look at three promising techniques that could make up the future of organ transplants: xenotransplantation, 3D bioprinting, and stem cell technology.?
A biotech spinout is a company that is created once it splits off from a parent company or university, often formed based on the research generated from the institution. A means to turn research into products of commercial value, the biotech industry has witnessed quite a few spinouts develop from research projects over the years. Here, we take a look at seven biotech spinouts to keep an eye out for in 2025.
Unlike current therapies that primarily focus on appetite suppression, Resalis Therapeutics’ lead program, RES-010, is a non-coding RNA drug candidate that targets underlying biological pathways to promote sustainable weight loss. To talk about ways to tackle obesity, and Resalis’ approach, our guest on this episode of the podcast is Alessandro Toniolo, CEO of Resalis Therapeutics.
Libra Therapeutics is a virtual company focused on developing novel disease-modifying therapeutics that restore the cellular balance that is disrupted in neurodegenerative diseases. This virtual biotech set-up brings with it the need for a secure data management platform that can store diverse screening, chemistry, and biology datasets from CRO partners, but also gives Libra users easy access, visualization, and comparative tools for data retrieval, review, and analysis across disciplines. For this, Libra has relied on CDD Vault since its inception.
??Enjoying these articles??Never miss a single publication of Labiotech by becoming a part of our community! Click here to join our mailing list.